Analysts Set Fractyl Health, Inc. (NASDAQ:GUTS) PT at $5.40

Fractyl Health, Inc. (NASDAQ:GUTS) has earned a consensus rating of “Hold” from the five brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $5.40.

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Finally, Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $8.00 to $2.00 in a report on Thursday, January 29th.

Fractyl Health Stock Down 1.6%

Shares of Fractyl Health stock opened at $0.58 on Tuesday. The company has a debt-to-equity ratio of 3.23, a quick ratio of 4.78 and a current ratio of 4.78. The stock has a market capitalization of $92.18 million, a PE ratio of -0.32 and a beta of 1.20. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $3.03. The company has a 50-day simple moving average of $0.48 and a two-hundred day simple moving average of $1.19.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.34. On average, analysts anticipate that Fractyl Health will post -0.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Rosalind Advisors Inc. purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $7,950,000. Centiva Capital LP purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $78,000. Jump Financial LLC purchased a new position in shares of Fractyl Health during the fourth quarter valued at approximately $57,000. Prelude Capital Management LLC purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $55,000. Finally, Scientech Research LLC purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $49,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.